The Filing Desk

Editas Medicine vs Voyager Therapeutics

Editas Medicine EDIT · Voyager Therapeutics VYGR · Biotechnology

Editas Medicine reported revenue of $40 million in fiscal 2025, about the same as Voyager Therapeutics' $40 million in fiscal 2025. Editas Medicine's revenue grew 25.4% in its latest year, and Voyager Therapeutics' fell 49.5%. Editas Medicine had an operating margin of -394.9%, against -326.6% at Voyager Therapeutics. Free cash flow was −$166 million at Editas Medicine and −$135 million at Voyager Therapeutics.

Side by side

Editas MedicineVoyager Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$40M$40M
Revenue growth25.4%−49.5%
Revenue growth a year, last 5 years−14.9%−25.1%
Gross margin——
Operating margin−394.9%−326.6%
Net margin−395.0%−296.5%
Free cash flow−$166M−$135M
Free cash flow margin−409.3%−334.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count7.8%1.8%
Last close$1.71$1.61
P/E at the last close——
Insider trades, last 12 monthssold $106,705sold $297,957
Piotroski F-score2 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Editas MedicineVoyager Therapeutics
Operating margin
Percent of revenue
Editas MedicineVoyager Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Editas MedicineVoyager Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Editas Medicine and Voyager Therapeutics pages.